… This study will analyze the efficacy and safety of sacubitril/valsartan compared to enalapril
in patients with chronic Chagas cardiomyopathy. As for the primary outcome, it will be …

… We have implemented all necessary measures and conducted rigorous testing to prove no
quantifiable levels of nitrosamine or azido impurities are to be found in its valsartan products. …

… weeks, indicating its competent efficacy and tolerability. Our findings may help medical
practitioners and patients to select the best angiotensin II receptor blocker against hypertension. …

… All blood samples were sent to our central laboratory for testing. … This study further confirmed
the effectiveness and safety of Sacubitril/Valsartan treatment in patients with HFrEF. In this …

… This study aims to investigate the dosage pattern, efficacy, and safety of sacubitril/valsartan
(Sac/Val) in Chinese heart failure with reduced ejection fraction (HFrEF) patients regarding …

… In the ESARHD-HF trial, Sacubitril/Valsartan will be compared to valsartan in HF patients
receiving maintenance hemodialysis for efficacy and safety. This study enrolled 118 patients, …

… the potential effectiveness of the novel compound [72]. This was a 36-week trial to evaluate
… efficacy, safety, and tolerability of sacubitril/valsartan compared to valsartan in 301 patients …

… Its efficacy and safety in end stage renal disease … in HD patients who received ARNI treatment
for heart failure. This case further supported the efficacy and safety of ARNI in HD patients …

… Thus, the Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of … the efficacy and
safety of sacubitril/valsartan in the prevention of cardiotoxicity in early breast cancer patients …

… We report on a population of 322 HF-rEF patients (75% male patients) switched to
sacubitril-valsartan. Of this total cohort, 25 patients were in the titration phase at the time of data …